Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARANA: Enzalutamide in localized prostate cancer
NCT03297385Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Netherlands Cancer Institute. Primary endpoints: Effects of enzalutamide on tumor downstaging at 3 months and Genetic and transcriptional changes caused by enzalutamide at 3 months. Started Aug 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03297385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297385.